A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2002
To evaluate the dose-response efficacy of E2020 (5 mg/day and 10 mg/day) versus placebo and verify superiority of E2020 to placebo in patients with severe AD using CIBIC-plus\* and SIB\*\* as the primary efficacy measures. Safety of E2020 will also be evaluated. (\*for overall evalution of clinical symtoms) (\*\*for cognitive function test)
Epistemonikos ID: 5d5c01fed9ced7d1ffb1517b45f0b367f2c4cc51
First added on: May 04, 2024